Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:00:35 EDT Tue 16 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MESO - MESOBLAST LTD SPON ADR EACH REP 10 ORD (REV SPLIT) - http://www.mesoblast.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MESO - Q3.14.73·4.750.74.731-0.439-8.5366.61,7369075.08  5.08  4.73110.24  1.6114:42:29Mar 2515 min RT 2¢

Recent Trades - Last 10 of 907
Time ETExPriceChangeVolume
14:42:29Q4.74-0.435
14:40:32Q4.735-0.43510
14:39:30Q4.765-0.40512
14:39:30Q4.75-0.42100
14:39:30Q4.75-0.421
14:39:30Q4.75-0.42100
14:39:30Q4.75-0.42100
14:39:30Q4.75-0.421,979
14:39:30Q4.75-0.421
14:39:30Q4.75-0.42125

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-25 22:34U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
2024-03-13 19:31U:MESONews ReleaseMesoblast Successfully Completes Placement and Accelerated Entitlement Offer
2024-03-10 19:54U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
2024-02-28 17:57U:MESONews ReleaseMesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
2024-02-26 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast
2024-02-14 19:47U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor ‚ ® (Rexlemestrocel-L) in Children With Congenital Heart Disease
2024-01-30 21:14U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
2024-01-18 18:36U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor ‚ ® (Rexlemestrocel-L) in Children With Congenital Heart Disease
2023-11-26 18:56U:MESONews ReleaseMesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
2023-11-21 18:32U:MESONews ReleaseMesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
2023-10-30 20:04U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
2023-09-26 06:19U:MESONews ReleaseJane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
2023-09-21 03:31U:MESONews ReleaseKey Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
2023-08-30 19:07U:MESONews ReleaseMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
2023-08-29 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast
2023-08-03 20:11U:MESONews ReleaseMesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
2023-07-30 20:31U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
2023-06-04 20:22U:MESONews ReleaseMesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
2023-05-25 19:29U:MESONews ReleaseMesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
2023-05-24 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast